Schwab Network on $LLY (Nov 12, 2026)
Eli Lilly is technically strong and the speaker expects a measured upward move: faster moving averages favor bulls, though it has not convincingly broken the 14.50 ceiling and RSI shows a bearish divergence. He prefers an options structure to capture upside while limiting downside, targeting 1560–1600 and an ideal 8–10% rise; the stock is expensive and hard for options, while healthcare should stay relatively strong into 2027.
Playing via YouTube may share device and playback data and use cookies. Privacy Notice · Google Privacy Policy
Jump to any passage
Your next choice is also in the healthcare sector. We have Eli Lilly. I mean, perhaps Eli Lilly's chart is more technically clear. So , what is your outlook for Lilly? A similar view.
The momentum is definitely there from a technical standpoint. But again, I fundamentally believe that the healthcare sector will continue to demonstrate relative strength as we enter 2027.
It is an expensive stock. It is difficult to structure options positions on it due to the size of the stock and the cost of the options as well. However, I still believe there are opportunities, and that's why when I looked at the trading example today, the focus was on structuring a deal around options.
Therefore, to some extent, we identify downside risks with the ability to capture upward price movements.
Good. Let's take a look at this arrow. Rick, judging from the chart, the trend seems to be in your favor here as well, and there has been a series of positive news events pushing it upwards, including the approval in China.
They are now treating sleep apnea with the drug "Fondo". I mean, there are a lot of potential positive developments for this name. But what do you see in the technical preparation?
Another strong chart here. Similar companies, as we mentioned here. This stock has risen 70% from those low levels we recorded near 8.50. But over the past year as a whole, i.e., the past 251 trading days, it rose by a similar amount to Johnson & Johnson, i.e., an increase of 42%.
So, once again, we recorded our highest level in 52 weeks today. This level reached 14.60. But we had some difficulty getting past this series of highs, this ceiling that we saw close to 14.50.
We have yet to see a strong and convincing upward breakout here. Today is still in its early stages. We still have one more trading day this week. So, anything is possible. But for now, the stock seems to be taking a slight break here.
There are also a few easy horizontal levels that traders might want to watch here. 13.30, which is the low point after our upward gap, and the subsequent low point we reached around the same level here.
Our gap also opened up around the 1300 level. Similarly, there is a gap here at 1230 and 1215, which is a little further down , but it is a similar area to watch based on our gaps and horizontal levels .
Right now, our 5-day exponential moving average in dark blue is around 14.25. So if we move down and break below that short-term moving average , our 21-day exponential moving average in turquoise is around 13.50 here.
That would be slightly below our trend line . But the moving averages here are what you want to see if you're optimistic. The faster averages all outperform the slower ones. They are all diverging from each other, indicating that the trend is still in favor of the bulls here, and we can see that the Relative Strength Index ( RSI), our momentum measure, is probably showing a slightly different reading.
We are in the overbought zone, but we are also recording a lower peak despite the price increase. So, this is a rather mixed message here. On one hand, the overbought zone is a sign of strength, but we have a bit of a bearish divergence here.
So, watch to see if the downtrend line will be broken, especially if we start pushing the price towards new record highs on the close here. Our size profile shows that we have a small node here, between 13.95 and 14.40.
Things become noticeably scarce until we return to this low level at 1190. So you might see faster price action if we start to break through some of these established levels. There has been extremely heavy trading lately as well, with several surges in trading volumes here.
Yes, we are now at 1447.77, so it is a much more expensive company in terms of Eli Lilly stock. But Dan, what specific execution prices do you look at when you evaluate Eli Lilly stock?
Yes, again Marley, as you pointed out, the nature of this stock being priced at $1400 to $1500 makes it unique in terms of trying to structure a trading model. But at the same time, I think identifying downside risks was one aspect of looking at this.
Therefore, today’s trading model is based on an execution price of 1460, and this is in January. Given that we are given more time, we will buy a contract at an execution price of 1460, then sell a contract at 1560, and sell an additional contract above that at 1660.
It is called a " call tree". It is the purchase of one contract and the sale of two contracts. This reduces the breakeven point to around $20, but at the same time it gives a large profit zone for the upside over the next two months.
Certainly, the ideal range is an 8 to 10% rise, but the breakeven point on the upside of this pattern is around 1735. That would mean a rise of 20% or more from the price at which it is currently trading.
It can certainly reach there, yes, but the idea here is to target an area between the 1560 and 1600 levels, and this model allows for that while identifying downside risks at the cost of the "options tree".
Good. So we have Eli Lilly now at 1448, and we're looking forward to a move, a measured upward move here.
What this channel has said about $LLY
Schwab Network has 7 calls on this stock; only the adjacent ones are shown.